tiprankstipranks
Advertisement
Advertisement

MBRX Stock Latest News

Moleculin Highlights Strong Market Interest in Annamycin AML Therapy
Company AnnouncementsMoleculin Highlights Strong Market Interest in Annamycin AML Therapy
8d ago
8K
MBRX
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO
PremiumCompany Announcements
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO
15d ago
8K
MBRX
Moleculin Biotech Releases Updated Investor Information Presentation
PremiumCompany Announcements
Moleculin Biotech Releases Updated Investor Information Presentation
18d ago
8K
MBRX
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO
PremiumCompany Announcements
Moleculin Highlights Annamycin Cardiac Safety Data at ASCO
22d ago
8K
MBRX
Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress and Safety Profile Support Unchanged $22 Price Target
PremiumRatings
Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress and Safety Profile Support Unchanged $22 Price Target
29d ago
MBRX
Buy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress Supports Unchanged $10 Price Target
PremiumRatingsBuy Rating Reiterated on Moleculin Biotech as MIRACLE Trial Progress Supports Unchanged $10 Price Target
1M ago
MBRX
Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30
Premium
The Fly
Moleculin Biotech expects first unblinding of MIRACLE trial data by June 30
1M ago
MBRX
Moleculin Nears First Unblinding in Pivotal MIRACLE Trial
Premium
Company Announcements
Moleculin Nears First Unblinding in Pivotal MIRACLE Trial
1M ago
8K
MBRX
Moleculin announces publication on cardiac safety profiloe of annamycin
PremiumThe Fly
Moleculin announces publication on cardiac safety profiloe of annamycin
1M ago
MBRX
Moleculin highlights favorable cardiac safety data for Annamycin
PremiumCompany Announcements
Moleculin highlights favorable cardiac safety data for Annamycin
1M ago
8K
MBRX
Moleculin Biotech issued liposomal Annamycin patent in Hong Kong
PremiumThe Fly
Moleculin Biotech issued liposomal Annamycin patent in Hong Kong
1M ago
MBRX
Moleculin Secures New Hong Kong Patent for Annamycin
PremiumCompany Announcements
Moleculin Secures New Hong Kong Patent for Annamycin
1M ago
8K
MBRX
Moleculin Highlights Promising Preclinical Data for L-ANN
PremiumCompany AnnouncementsMoleculin Highlights Promising Preclinical Data for L-ANN
2M ago
8K
MBRX
Moleculin Biotech Stockholders Approve Warrant Share Issuance
Premium
Company Announcements
Moleculin Biotech Stockholders Approve Warrant Share Issuance
2M ago
8K
MBRX
Moleculin Biotech management to meet with Maxim
Premium
The Fly
Moleculin Biotech management to meet with Maxim
2M ago
MBRX
Moleculin Biotech files to sell 6.37M shares of common stock for holders
PremiumThe Fly
Moleculin Biotech files to sell 6.37M shares of common stock for holders
3M ago
MBRX
Moleculin Biotech announces enrollment milestone in MIRACLE trial
PremiumThe Fly
Moleculin Biotech announces enrollment milestone in MIRACLE trial
3M ago
MBRX
Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout
PremiumCompany Announcements
Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout
3M ago
8K
MBRX
Moleculin Biotech: Attractive Risk/Reward Ahead of Pivotal Annamycin Phase 3 Readout Supports Buy Rating and $10 Target
PremiumRatings
Moleculin Biotech: Attractive Risk/Reward Ahead of Pivotal Annamycin Phase 3 Readout Supports Buy Rating and $10 Target
3M ago
MBRX
Moleculin Biotech Updates Investors with New Corporate Presentation
PremiumCompany AnnouncementsMoleculin Biotech Updates Investors with New Corporate Presentation
3M ago
8K
MBRX
Moleculin Biotech reports FY25 EPS ($28.42) vs. ($189.14) last year
Premium
The Fly
Moleculin Biotech reports FY25 EPS ($28.42) vs. ($189.14) last year
3M ago
MBRX
Moleculin Biotech sees cash runway into 3Q26
Premium
The Fly
Moleculin Biotech sees cash runway into 3Q26
3M ago
MBRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >